The Securities and Exchange Commission has announced that it has resolved civil FCPA charges against the French drug company, Sanofi, and its Kazakh and Middle Eastern subsidiaries. The company will pay $25 million to settle allegations that it participated in bribery schemes to secure government tenders and increase prescriptions.
September 4, 2018
Pharmaceutical giant charged with bribery
Related by Topic
New Post
The Netherlands imposes €25.8 million fine on Fleurette Properties for engaging in bribery in the DRC
March 13, 2026
News Alert
New Post
One Size Fits All: DOJ’s First Department-Wide Corporate Enforcement Policy
March 13, 2026
Insight
New Post
Former owners of medical device company indicted for roles in an international laundering and bribery scheme
March 9, 2026
News Alert